Production Linked Incentive (PLI) scheme for pharmaceuticals has attracted cumulative investments of ₹41,943 crore as of December 2025, more than doubling the initial commitment of ₹17,275 crore over six years. The remarkable growth clearly reflects strong industry participation and sustained capital deployment across the pharmaceutical manufacturing value chain.
Strong Growth in Production and Exports
Alongside rising investments, the scheme has significantly boosted production output. Cumulative sales have reached ₹3,35,036 crore across 1,988 products, demonstrating robust manufacturing expansion. Notably, exports account for ₹2,15,248 crore, highlighting India’s growing integration into global pharmaceutical supply chains. As a result, the country continues to strengthen its position as a key global supplier of medicines and pharma products.
Accelerating API Localisation and Import Substitution
A major focus of the PLI scheme has been to reduce import dependence by strengthening domestic production of critical inputs such as Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs) and Drug Intermediates. Out of the total product portfolio, 726 products fall under these categories, with 191 being manufactured in India for the first time. Consequently, these segments alone have contributed ₹28,067 crore in domestic sales. The shift marks a significant step toward self-reliance in bulk drugs, reducing reliance on overseas suppliers and improving supply chain resilience.
Bulk Drugs Scheme Expands Capacity and Regional Development
Launched in 2020, the PLI scheme for bulk drugs has also exceeded expectations. Investments have reached ₹4,814 crore, surpassing the initial commitment of ₹4,329.95 crore. The initiative has contributed to regional industrial growth. For instance, six new manufacturing units have been commissioned in Visakhapatnam, supporting development in an identified aspirational region.
Rising Incentives Reflect Scheme Momentum
Government incentive disbursements have steadily increased, underlining the scheme’s growing traction. While the sector continues to expand, regulatory compliance remains a key priority. As reported by manufacturingtodayindia.com, overall, the PLI scheme has emerged as a powerful catalyst for transforming India’s pharmaceutical sector. By driving investments, boosting domestic manufacturing, and enhancing export competitiveness, the initiative is paving the way for a more resilient, self-reliant, and globally competitive pharma industry.
